BioSpace News Archive

Drug Development

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria, whose symptoms are not adequately controlled by H1 antihistamines.

February 24, 2024
·
8 min read
Drug Development

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. announced positive 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria refractory to antihistamines, including patients with biologic-refractory disease.

February 24, 2024
·
9 min read
Policy

Virtual Incision Receives FDA Authorization for the MIRA Surgical System as the First Miniaturized Robotic-Assisted Surgery Device

Virtual Incision Corporation announced the U.S. Food and Drug Administration has granted marketing authorization of the MIRA™ Surgical System, the world’s first miniaturized robotic-assisted surgery device, for use in adults undergoing colectomy procedures.

February 24, 2024
·
6 min read